Quoin Pharmaceuticals Ltd... (QNRX)
NASDAQ: QNRX
· Real-Time Price · USD
6.19
-0.07 (-1.16%)
At close: May 09, 2025, 3:58 PM
6.39
3.23%
After-hours: May 09, 2025, 05:15 PM EDT
-1.16% (1D)
| Bid | 6 |
| Market Cap | 1.58M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -8.98M |
| EPS (ttm) | -66.85 |
| PE Ratio (ttm) | -0.09 |
| Forward PE | -15.47 |
| Analyst | Buy |
| Ask | 6.65 |
| Volume | 5,787 |
| Avg. Volume (20D) | 210,327 |
| Open | 6.27 |
| Previous Close | 6.26 |
| Day's Range | 6.18 - 6.34 |
| 52-Week Range | 5.01 - 54.95 |
| Beta | 1.60 |
About QNRX
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol QNRX
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for QNRX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts1 month ago
+38.19%
Quoin Pharmaceuticals shares are trading higher af...
Unlock content with
Pro Subscription
2 months ago
+15.4%
Quoin Pharmaceuticals shares are trading higher after the company announced its whole body data from ongoing pediatric netherton syndrome study.
3 months ago · accessnewswire.com
Skinvisible Reports Licensee Success in Netherton Syndrome Clinical StudiesLAS VEGAS, NV / ACCESS Newswire / January 23, 2025 / Skinvisible Pharmaceuticals, Inc. ("Skinvisible" or "the Company"), (OTCQB:SKVI), an innovative topical and transdermal pharmaceutical research and...